ADC外包

Search documents
大行评级|里昂:对药明合联持有长期正面看法 目标价上调至70.7港元
Ge Long Hui· 2025-08-21 04:06
Group 1 - The core viewpoint of the report is that WuXi AppTec's revenue and adjusted net profit for the first half of the year increased by 62% and 50% year-on-year, respectively, aligning with previous profit forecasts [1] - The strong demand from the U.S. market has driven a year-on-year growth of 58% in total unfulfilled orders and 48% in new signed orders during the period [1] - Management has raised the revenue growth guidance for 2025 from 35% to 45%, primarily due to robust demand for ADC outsourcing and a solid order backlog [1] Group 2 - The report maintains a long-term positive outlook on WuXi AppTec, reiterating the "Outperform" rating and raising the target price from HKD 47.3 to HKD 70.7 [1] - Revenue forecasts for 2025 to 2027 are projected to grow by 45%, 31%, and 27%, respectively [1]